Influence of Menopause on the Periodontium

Suicide Among Females with Pregnancy: A Retrospective Study

Influence of Menopause on the Periodontium

Molar Pregnancy with Viable Foetus Progressed to Term – Case Report

Assessment of Child Psychiatric Disorders

Gestational Diabetes
Journal Watch

75 • The Millennium Villages project in Africa
• Management of type 2 diabetes in children and adolescents
• Treatment for infants of mothers who present late in pregnancy with an untreated HIV-1 infection
• Zidovudine, lamivudine, and ritonavir-boosted lopinavir for HIV-infected children

76 • Neonatal screening with pulse oximetry for critical congenital heart defects: Systematic review and meta-analysis
• Oral immunotherapy for egg allergy in children

Editorial Board

Board Director, Pediatrics
Professor Pik To Cheung
Associate Professor
Department of Pediatrics
and Adolescent Medicine
The University of Hong Kong

Board Director, Obstetrics and Gynaecology
Professor Pak-Chung Ho
Head, Department of
Obstetrics and Gynaecology
The University of Hong Kong

Professor Biran Affandi
University of Indonesia
Dr Karen Kar-Loon Chan
The University of Hong Kong
Associate Professor Oh Mui Chay
KK Women’s and Children’s Hospital, Singapore
Associate Professor Annette Jacobsen
KK Women’s and Children’s Hospital, Singapore
Professor Raham Jamil
Universiti Kebagsaan Malaysia
Dato’ Dr Ravindran Jegarasothy
Hospital Kuala Lumpur, Malaysia
Associate Professor Kenneth Kwee
KK Women’s and Children’s Hospital, Singapore
Dr Sio Keung Lam
Kwong Wah Hospital, Hong Kong
Professor Terence Lau
Chinese University of Hong Kong
Dr Sue-Yen Leong
The University of Hong Kong
Dr Tak Yeung Leung
Chinese University of Hong Kong
Professor Tai-Kin Lim
Chang Gung University, Taiwan
Professor Somsak Lalong
Ramathibodi Hospital, Thailand
Professor Lucy Chai-See Lun
University of Malaya, Malaysia
Professor SC Ng
National University of Singapore

Professor Hextan Yuen-Sheung Ngan
The University of Hong Kong
Professor Carmenita D Padilla
University of the Philippines Manila
Professor Seng-Hock Ong
National University of Singapore
Dr Tatang Kusuman Sani
University of Yarumanagara, Indonesia
Professor Perla D Santos Ocampo
University of the Philippines
Associate Professor Alex Se
KK Women’s and Children’s Hospital, Singapore
Dr Rulan Subramaniam
Fetal Medicine and Gynaecology Centre, Malaysia
Professor Walfrido W Sumpaico
MCU-DFT Medical Foundation, Philippines
Professor Cheng Lim Tan
KK Women’s and Children’s Hospital, Singapore

Associate Professor Kok Hian Tan
KK Women’s and Children’s Hospital, Singapore
Dr Suresha Tananeepanichkul
Chulalongkorn University, Thailand
Professor Eng-Hsiong Tay
Thomson Women’s Cancer Centre, Singapore
Professor Guriardi H Wiknjasstra
University of Indonesia
Dr PC Wong
National University of Singapore
Dr George SH Yeo
KK Women’s and Children’s Hospital, Singapore
Professor Hui-Kim Yap
Thomson Women’s Cancer Centre, Singapore
Professor Gulardi H Wiknjasstra
University of Indonesia
Dr PC Wong
National University of Singapore

Indian Editorial Board

Chancellor & Gynaecology
Dr. JB Sharma
Additional Professor, All India Institute of Medical Sciences, New Delhi
Dr. Asha Pherwani
PD Hinduja Hospital & Research Centre, Mumbai

Pediatrics
Associate Professor Bharat J Parmar
BJ Medical College & Civil Hospital, Ahmedabad
Assistant Professor Deepak Chawla
Government Medical College & Hospital, Chandigarh
Dr. Sangrati Sharma
LRS Institute of Tuberculosis & Respiratory Disease, New Delhi
Dr. Asha Pherwani
Review Article
Paediatrics

77 Assessment of Child Psychiatric Disorders
This article focuses on key stages in the assessment of psychiatric disorders in children and adolescents. Key points on how the interview with an adolescent may be conducted in an ‘adolescent-friendly’ fashion are also discussed.

Helen Bruce, Navina Evans

In Practice

82 Case of the Month: Woman Presented with a Soft Globular and Pedunculated Mass in Labia Majora
Sreelatha Sampath Kumar, Ashwini Rani, BR Vani

Review Article
Obstetrics

83 Suicide Among Females with Pregnancy: A Retrospective Study
Suicide is an important indicator of mental and social health of society. It is a complex phenomenon involving socio-cultural, psychological and biological elements. Pregnancy is a special risk factor for suicide attempts among females. Low suicide rate during pregnancy and in the two years following could establish the ‘protective effect of maternity’. The aim of the present study is to know the prevalence and profile of suicide in pregnant women.

Sanjeev Lalwani, Raghvender Bagla, Mamta Sood, Chittranjan Behera, Daya Nand Bhardwaj
87 Influence of Menopause on the Periodontium

Menopause is defined as the permanent cessation of menstruation due to loss of ovarian follicular function, and usually takes place between 45 and 55 years of age. During menopause, periodontal symptoms can differ for each woman. Patients need proper guidance from the physicians regarding the influence of menopause on the periodontium and reference to a periodontist at the first sign of periodontal disease because both the conditions can be managed better when diagnosed in the early stages.

Roby V Emmanuel, Shiba Neelakantan K

91 In Practice (Answer)

93 Molar Pregnancy with Viable Foetus Progressed to Term – Case Report

Madhusree Vijayakumar, Roopashree

98 Gestational Diabetes

Historically, there has been a lot of controversy over most aspects of gestational diabetes mellitus (GDM) as well as the relationship between GDM and type II diabetes mellitus. Recently, several major studies have substantially resolved these areas of controversy.

LL Chan, WL Lau, WC Leung
The Millennium Villages project in Africa

The Millennium Villages project began in nine African countries (Nigeria, Mali, Senegal, Ghana, Uganda, Kenya, Rwanda, Tanzania, and Malawi) in 2006. In each country, a rural population (average, 35,000 people) with high levels of poverty and undernutrition was selected. Finance amounting to around US$120 per person was provided annually to support agriculture, the environment, business development, education, infrastructure, and health, in partnership with communities and local governments. Average spending per person was $27 at baseline and $116 by year 3. There were improvements in water supplies and sanitation, poverty levels, food security, stunting, and malaria prevalence at Millennium Village sites after 3 years. Under-5s mortality fell by 22% in these sites and by 33% relative to matched comparison sites. Provision of many maternal–child health interventions was improved.

The multifaceted intervention was beneficial in several ways including reduced child mortality.


Management of type 2 diabetes in children and adolescents

The increased prevalence of obesity in children and adolescents has led to an increased incidence of type 2 diabetes. The physical and emotional challenges of adolescence, together with the increased frequency of obesity and diabetes in underprivileged communities, add to the difficulties of diabetes control. Three treatment approaches have been compared in a US multicentre trial.

A total of 699 patients aged 10–17 years with type 2 diabetes (mean duration, 7.8 months) and obesity (body mass index, 85th percentile or higher for age and sex) were randomized to metformin alone (M), metformin plus rosiglitazone (MR), or metformin plus a weight-loss lifestyle intervention (MW). Over an average follow-up of 3.9 years, loss of glycaemic control (glycated haemoglobin at least 8% for 6 months or sustained metabolic decompensation needing insulin) occurred in 45.6% of participants overall. The group rates for this outcome were 51.7% (M), 38.6% (MR), and 46.6% (MW). MR was significantly better than M, but MW was not significantly different from M or MR. MR was the best of the three options. Most young people with type 2 diabetes will probably need combination drug therapy or insulin within a few years of diagnosis.


Zidovudine, lamivudine, and ritonavir-boosted lopinavir for HIV-infected children

For mothers and infants, who have previously been exposed to nevirapine, treatment of human immunodeficiency virus (HIV)-1 infection with a regimen including ritonavir-boosted lopinavir is better than...
treatment with a nevirapine-based combination. The best treatment for children not previously exposed to nevirapine is uncertain. Now, a trial in six countries in sub-Saharan Africa and India has shown that a ritonavir-boosted lopinavir-based regimen is better than a nevirapine-based regimen for young children who are nevirapine-naive.

A total of 287 nevirapine-naive HIV-infected children aged 2–36 months were randomized to zidovudine and lamivudine with either nevirapine or ritonavir-boosted lopinavir. The median proportion of CD4+ T-cells was 15% and median plasma HIV-1 RNA level 5.7 log_{10} copies/mL. Virological failure or treatment discontinuation by week 24 occurred in significantly more children in the nevirapine group (40.8% vs 19.3%). Drug resistance was present in 19 of 32 children in the nevirapine group tested at the time of virological failure. Mortality was greater in the nevirapine group (10/147 vs 3/140), and drug toxicity was also greater.

The results were better with the ritonavir-boosted lopinavir-based regimen, but these researchers point to difficulties in introducing this treatment: the liquid formulation is unpleasant to taste and deteriorates in hot temperatures, and the cost is twice that of the nevirapine-based regimen. New drug formulations are needed urgently.


**Neonatal screening with pulse oximetry for critical congenital heart defects: Systematic review and meta-analysis**

Babies with congenital heart defects may be discharged from hospital before a diagnosis is made and may subsequently become suddenly and critically ill. A new systematic review and meta-analysis has confirmed that pulse oximetry screening of asymptomatic newborn babies is highly specific and moderately sensitive for the detection of critical congenital heart defects.

The review included 13 studies (229,421 babies). The sensitivity of pulse oximetry was 76.5% and the specificity 99.9%. The false-positive rate was 0.50% in the first 24 hours after birth and 0.05% when done later.

It is concluded that pulse oximetry screening should be introduced widely.


**Oral immunotherapy for egg allergy in children**

By the age of 2.5 years, around 2.5% of children have developed egg allergy. Complete dietary avoidance may be difficult. Now, a multicentre US trial of oral immunotherapy has given positive results.

The trial included 55 children aged 5–11 years with egg allergy without a history of severe anaphylaxis. All had raised levels of egg-specific IgE. Randomization was to oral immunotherapy (40 children) or placebo (15 children). Immunotherapy consisted of giving egg white powder in three phases, in increasing doses up to 2 g per day. Challenges with egg white were performed at 10 and 22 months. After a 5-g challenge at 10 months, no allergic symptoms (or mild symptoms) occurred in 55% (immunotherapy) vs none (placebo). At 22 months, 75% of children in the immunotherapy group passed a 10-g challenge. At 24 months, 29 of the 30 children who passed the 22 months’ challenge were re-challenged and 11 passed. All of the children who passed the 24 months’ challenge were able to eat egg at 30 and 36 months.

Oral immunotherapy may be successful in some children with egg allergy.

This article is divided into two stages: assessment of psychiatric disorders in children and assessment of psychiatric disorders in adolescents. The general pointers at the beginning of the article are of relevance to both groups, as are the comments about early history.

**SETTING THE STAGE**

The assessment of a child or adolescent usually takes place over several meetings, using information from several different sources. An initial assessment interview is a key time to begin the therapeutic process of engagement with a family, and it is important to try to get it right.

The setting of the interview may vary hugely, from an accident and emergency department or a community location such as a schoolroom that is used for many other purposes, to a clinic setting with a room set up in an age-appropriate way for this purpose. Consideration must always be given to the safety of the child and the family, as well as that of the interviewers.

**WHOM TO SEE**

With a younger child, it is usually helpful to meet with the whole family at the start of the interview, but at some stage in the assessment, the parent(s) or guardian should be seen without the child being present. Where it is age appropriate, a younger child must also be given time to speak to the interviewers—either focusing the interview on them with the family present or meeting with the child alone. An adolescent will usually wish to be seen for some of the assessment without their parents.
FAMILY INTERVIEW

The interview should begin by making the family welcome and putting them at ease. What do the family see as the problem, and who has the problem? How are they trying to deal with it at present? What have they already tried, and what help have they already received? How does the problem affect their lives?

One strategy the assessor may use is to ask the family to work together in the session on an exercise, such as drawing up a family tree. This gives the assessor an insight into how family members relate to one another and also into the presenting problem. Are the parents sensitive to the child’s communications? How do they respond? What is the parents’ own relationship like? Is one family member ignored?

INTERVIEW WITH THE CHILD

With the younger child, it may not be possible formally to examine the child’s mental state, and the clinician will need to rely on observation. This should include an observation of the child’s behaviour, interactions with family, interactions with clinicians, and play. Key things to include are shown in Table 2.

At the end of the interview with the child, a helpful technique is to ask the child ‘If you had three wishes, what would you wish for?’ In response to this question, the child will often give useful information about their situation, fears and worries, using terms and a context that is meaningful to them.

INTERVIEW WITH THE PARENT(S) OR CARER

It is important to obtain from the parent(s) a thorough description of the current problem, as well as an account of the child’s development and medical and school history. The key points are summarized in Table 3.

It is best if this information can be obtained from an interview with the parent or guardian without the child being present, to allow them to have a frank discussion and to give full details to the clinician.

PHYSICAL EXAMINATION AND INVESTIGATIONS

Most children who attend child mental health services are not routinely medically examined. It is important that consideration is given to a physical examination, if one has not already been done before the child is being seen in the clinic by the general practitioner or community paediatrician. Reasons for this assessment include the possibility of an underlying undetected physical condition that has caused the child’s difficulties, or the prescription of medication that could have physical side effects, such as risperidone or methylphenidate. Guidelines can be found that are relevant to each medication and indicate the essential elements of physical examination. An example of this is the European Clinical Guidelines for Hyperkinetic Disorder, but most National Health Service Trusts also have their own prescrib-
ing guidelines that state minimum levels of physical investigations required in their policies.

A baseline height and weight should always be recorded. Where there is suspicion of an underlying medical condition, a full physical examination is essential. A full neurological examination may also be required if the history is indicative of a neurological disorder such as developmental delay, epileptic fits or loss of skills. Other indicators include a history or physical appearance that suggests the child could have a congenital syndrome. Useful pointers to congenital syndromes include learning difficulty, dysmorphic features (including unusual facial features) and extreme values for height, weight or head circumference.¹

Most children do not require further medical investigations unless there is a clinical indication or abnormalities have been found on the physical examination. However, it is important to carry out appropriate blood tests if medication is being considered.

OTHER SOURCES OF INFORMATION

Before the assessor seeks other sources of information (from educational or social services, for example), it is important to ensure that parental consent has been obtained for this. Other agencies involved with the family or child may have information that is useful in helping to understand the child’s problems. Schools can provide particularly valuable accounts of a child’s difficulties. It is usually best to obtain structured reports, in the form of a set of specific enquiries. Potential informants include the child’s class teacher and the school’s Special Educational Needs Coordinator (SENCO). Depending on the nature of the child’s problem, the enquiry can be supported by standardized questionnaires that are available for teachers, such as the Conners’ Rating Scales for Hyperactivity/Inattention. A school or nursery observation by the clinician (if resources allow) will also yield valuable information.

PUTTING IT ALL TOGETHER/ FORMULATION

First, the clinician will need to consider whether the child’s behaviour, emotional state or presenting difficulty is abnormal. It must be carefully considered whether a symptom is abnormal in relation to a child’s age and gender, culture or developmental stage. The symptom needs to be assessed as persistent, severe, frequent and of a sufficient extent to be considered abnormal. It is important to know whether the symptom is leading to functional impairment in the everyday life of the child. Four main criteria can be used to assess impairment:

- Interference with a child’s development
- Social restriction
- Suffering or distress to the child
- Effect on others

Different aspects of the child’s problems are best recorded using a multiaxial framework such as that of the International Classification of Diseases, tenth revision (ICD-10), which records the following:

- Axis I: Clinical Syndrome
- Axis II: Disorders of Psychological Development
- Axis III: Mental Retardation
- Axis IV: Medical Illness
- Axis V: Psychological Disorders

An adequate formulation of the child’s difficulties requires the examiner to piece together the presenting features of the problem, with any aetiological factors, and to comment on the differential diagnosis, management and prognosis. This evaluation will form the basis on which any intervention is planned.

ASSESSMENT OF THE ADOLESCENT

The general principles of assessment outlined above apply to any age of child. However, it is particularly important to bear in mind that the range of disorders seen in adolescence may differ from those found in younger children. (Table 4) There are some useful ba-
Establish the characteristics of the young person’s problem, even if it is not possible to formulate a diagnosis within the framework of ICD-10. It is sometimes sufficient to take a symptom-based or problem-focused approach to management.

Pay attention to risk assessment and associated management. This is a very important aspect of care, because risk both to the individual and to others (within and outside the family) is more of an issue in adolescent disorders. The psychiatrist plays a crucial role in risk management, and should attempt to manage anxiety within the young person’s social network.

Have a good understanding of strengths, resilience and protective factors. These can be exploited in the management plan and enhance outcome.

To establish predictors of good outcome at the outset of the management plan, in order to improve the child’s prognosis.

There are key areas where the assessment of adolescents differs from the equivalent assessment of younger children. It is important to take into account developmental issues and to have a good understanding of the particular young person’s stage of emotional, cognitive and psychological development, which may differ according to their physical maturity. Be aware that the individual’s autonomy must be given due respect. This issue can cause tension in the assessment phase, but should not be ignored. Confidentiality is linked with this issue. Although it may not always be possible to guarantee confidentiality, the young person is entitled to a full explanation of how this right will, as far as possible, be respected.

Many patients have their first encounter with mental health services during their adolescence. The nature of this experience will affect their future compliance and engagement, so it is especially important to consider the long-term implications of their interaction with professionals at this stage.

When seeing the adolescent, it is helpful to establish what they personally see as the problem. They may not agree that they have a problem at all. Even if they do not agree with the parent or referrer, the examiner can still establish a rapport, and it is important to engage with the young person. The issue of confidentiality and its limits should be established. The process of assessment should be explained clearly. A psychiatric mental state examination should be carried out. At the end of the interview, it is important to ask the young person whether there is anything else they would like to talk about or that you should know which would help you in your assessment. It is also important to ask whether they have any questions for you.

The family interview is useful for gathering information. It is also a helpful space for observing interactions and gaining some insight into how the family members relate to one another, the adolescent’s role in relation to the others, and how the particular family is negotiating the life-cycle changes involved at this stage of the young person’s development.

The parents can be interviewed together with the young person, or separately. Many young people want to know what is being said about them, and they should not be excluded. At times, it may be more appropriate for the young person and the parent(s) to be seen separately, for instance, when the young person is extremely agitated or unwell, or...
if the parents are concerned about talking in front of the young person. If this is done, the young person should be informed that the discussion is taking place and it should be made clear to all involved what level of information will be shared. It is important not to be drawn into colluding with any secrets between family members.

As with an assessment of a younger child, the aim is to gain a comprehensive picture. In addition to all of the information outlined in Table 3, it is also important to obtain a sexual, forensic, and drug and alcohol history.

The physical examination should be conducted when there are clinical indications. Appropriate investigations should be considered to rule out organic causes for the presentation.

As with a younger child, it is important to gather information from as many sources as possible in order to build an accurate and helpful picture. This will enable the application of a meaningful formulation and plan. However, it is important to be mindful of confidentiality and to be explicit about the limits and the process of sharing any confidential information with the young person.

The formulation is of particular importance. It should be phrased in such a way that the young person can be engaged in the plan of treatment and management. Adolescents are aware of their autonomy, and their co-operation is vital. As well as devising an account of the origins of the child’s problem and its impact on their day-to-day functioning, the formulation should also reflect on sources of strength and resilience at the personal and family level. The ICD-10 multiaxial framework remains useful as a way of summarizing the issues relevant to the child’s difficulties, as these are often complex and require complex solutions.


About the Authors

Dr Bruce is Consultant Child and Adolescent Psychiatrist at East London NHS Foundation Trust and is Honorary Clinical Senior Lecturer at Barts and the London School of Medicine and Dentistry, London, UK. Dr Evans is Consultant Child and Adolescent Psychiatrist working in a Tier Four Specialist Adolescent Service in East London. She also is Clinical Director for CAMHS in the East London Foundation NHS Trust.

REFERENCES

Case of the Month

Woman Presented with a Soft Globular and Pedunculated Mass in Labia Majora

Sreelatha Sampath Kumar, Ashwini Rani, BR Vani

Case Report
A 39 year old woman presented with a mass arising from the right labia majora since 10 years. It had gradually increased in size. The mass was globular, soft in consistency, non-tender pedunculated (attached to the labium by a stalk) and measured 6X5 cms (Figure 1). The skin overlying the mass was normal. A clinical diagnosis of lipoma was made. It was completely excised and sent for histopathological examination (Figure 2).
Suicide Among Females with Pregnancy: A Retrospective Study
Lalwani Sanjeev, Raghvender Bagla, Mamta Sood, Chitraranjan Behera, Daya Nand Bhardwaj

INTRODUCTION

Suicide is an important indicator of mental and social health of society. It is a complex phenomenon involving socio-cultural, psychological and biological elements. The number of suicides in India during the decade (2000–2010) has recorded an increase of 23.9% (from 1,08,593 in 2000 to 1,34,599 in 2009). With 18.3% rise in population, increasing trend in suicide rate is observed during 2006 (10.5) to 2010 (11.4).

Pregnancy is a special risk factor for suicide attempts among females. Oates M has reported suicide though rare but as leading cause of maternal deaths. In contrary to this Appleby and Marzuk et al, reported that women during pregnancy have a low risk of suicide. Low suicide rate during pregnancy and in the two years following could establish the “protective effect of maternity”. Youchah et al mentions that pregnant women rarely commit suicide but, psychological factors, substance abuse and other intervening factors make this generalisation unreliable.

We have earlier reported that at our hospital, autopsies were conducted on 19.2% of females over 5 year period. Out of these, 89.2% had died because of unnatural deaths; suicide was an important cause comprising of 40% of total unnatural deaths. The present report was prompted by the observation that there were many pregnant females in this sample, though they were not separately analysed. Although literature is available from various countries, there is deficiency of literature addressing the specific issue of suicide among pregnant females in India. There is need for such studies so as to increase awareness and understanding of suicide among pregnant females and plan strategies for its prevention. The aim of the present study is to know the prevalence and profile of suicide in pregnant women.
MATERIAL AND METHODS

The present study includes all cases of suicidal death of pregnant females on whom autopsy was conducted in the Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi (a tertiary care hospital) from January 1991 to December 2010. The data were collected from autopsy reports, inquest papers and clinical records and analysed as per age of victim, duration of pregnancy, cause and manner of death.

RESULTS

In the study period from January 1991 to December 2010, a total of 235 maternal deaths were reported, out of these 81 (34.50%) cases were of suicidal deaths pertaining to pregnant females. Among these, commonest age group of victims involved was of 21–25 years (n=39, 48.15%) followed by 16–20 years (n=20, 24.69%) and 26–30 years (n=19, 23.46%) (Table 1). Majority of pregnant females who committed suicide during first and second trimester (Table 4). Commonest sex of the foetus determined was male in 25 (30.86%), female in 14 (17.28%) cases and was not possible to determine in 37 (45.68%) cases (Table 5). Hanging was the commonest method used to commit suicide (n=46, 58.02%) followed by poisoning (n=20, 24.69%) and burns (n=12, 14.81%) (Table 6). Viscera’s were sent for chemical analysis in 41 (50.62%) cases.

DISCUSSION

Suicide is one of the important and potentially preventable causes of maternal mortality. In our study, 81 (34.50%) cases were of suicide among deaths pertaining to pregnant females during autopsy. In the study from Bangladesh by Yusuf et al reported that out of 425 women who were pregnant when they died due to injuries, 201 (47.4%) were due to suicide. The results noted in our report are lower, this could be because the data was collected from health service functionaries in all health facilities in Bangladesh. From India, we could not find any study related to suicide in pregnancy. However, Lal et al reported that out of 219 deaths of mothers, slightly over 20% of accidental deaths were due to burns and suicide.

The commonest age group of pregnant females committing suicide was 21–25 years. This is in line with national data on suicide in India also suggest 15–29 years of age group with maximum number of suicidal deaths among females and our previous study. However, Appleby reported that within the population of pregnant women, teenagers are at greater risk to commit suicide. Out of nine suicides among pregnant women reported in Virginia, USA, 4 were in the age group of 19–22 years.

Majority of pregnant females who committed

<table>
<thead>
<tr>
<th>Table 1. Age of victim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years</td>
</tr>
<tr>
<td>16–20</td>
</tr>
<tr>
<td>21–25</td>
</tr>
<tr>
<td>26–30</td>
</tr>
<tr>
<td>31–35</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Marital status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marital status</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Married</td>
</tr>
<tr>
<td>Unmarried</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Type of inquest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inquest</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>SDM</td>
</tr>
<tr>
<td>Police</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

SDM:
suicide in our sample, were married which is in line
with national data. The causes of suicide among
married pregnant females in India could include
family problems, illness (prolonged illness, mental
illness) and dowry related disputes. Some of the
pregnant females (about 6%) were unmarried also.
The causes of suicides among unmarried pregnant
females could be love affairs, suspected or illicit
relations, and illegitimate pregnancy.³ In our study,
magistrate inquest under section 176 Cr PC (Crimi-
nal Procedure Code) regarding dowry related deaths
was held in 32 (39.51%) of cases wherein inquest
was held to look into the harassment or cruelty
by husband or parents in laws. Martin et al have
also reported strong relationship between suicide
during pregnancy and intimate partner violence.²¹

Our study did not show any significant differ-
ence in suicide committed in first and second
trimester. Whitlock and Edwards found that preg-
nant women who attempted suicide did so primar-
ily during the first two trimesters of pregnancy.²²

However, Appleby reported that most of the cases
of suicide occurred in second trimester.⁶

In contrast to Hawton et al,⁸ reporting that
women are less likely to die violently, in the present
study, hanging was the commonest method used
to commit suicide followed by self-poisoning
and self-immolation. Our findings are also in conformity
with national data on suicide wherein hanging and
poisoning are reported to be the leading causes
of suicide among females.³ Similar results were
reported by Aaron et al,²³ from South India. Although
self-immolation was used to commit suicide in 12
cases (14.81%), these numbers may not be indica-
tive of actual number of fatalities due to self im-
olation as our institution lack burn center, therefore
all those cases with even remote chance of survival
would have been taken to health care set up having
specialised treatment facility for thermal inju-
ries. Our study includes only those cases in which

<table>
<thead>
<tr>
<th>Table 4. Gestational age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>First trimester</td>
</tr>
<tr>
<td>Second trimester</td>
</tr>
<tr>
<td>Third trimester</td>
</tr>
<tr>
<td>Not known</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 5. Foetal sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex of foetus</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>Undetermined</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 6. Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cause of death</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Poisoning</td>
</tr>
<tr>
<td>Sulfos</td>
</tr>
<tr>
<td>Others</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>OP</td>
</tr>
<tr>
<td>Hanging</td>
</tr>
<tr>
<td>Self immolation</td>
</tr>
<tr>
<td>Drowning</td>
</tr>
<tr>
<td>FFH</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
In this study, no information was available regarding mental illness in the pregnant females who committed suicide. However, subsyndromal psychiatric symptoms and psychiatric disorders are common among pregnant women and may occur in about 10–41.2% of them. National data also suggest that among females who committed suicide due to any illness, mental illness was the second leading contributor. In pregnancy, although psychosis is rare, depressive and anxiety disorders are common. Suicidal ideations have also been reported in pregnant women. World Health Organization (WHO) has recognised mental disorders as indirect causes of maternal deaths as these are the conditions not directly related to obstetric cause but can be worsened by the pregnant status. Pregnancy is also reported to be associated with a high rate of mental health disorders.

**LIMITATION**

As reported by other authors, retrospective evaluation of data on suicide and reliance on death certificates provided very little or no information regarding precipitating circumstances on suicide. (Palladino et al., Hoyet DL). As this is hospital based study, the findings may not be generalisable to the general population.

**CONCLUSION**

In the present study, over 2 decades, about 34.5% of suicidal deaths in pregnant females were identified in a tertiary care centre. Majority of them and pregnant women in first two trimesters. Hanged was the commonest method used for committing suicide. These findings highlight the need for conducting community based studies to delineate correlates and determinants of suicide in pregnant females which will further help in developing strategies for its prevention.

**About the Authors**

Dr Sanjeev Lalwani is a Associate Professor, Dr Raghvender Bagla is a Senior Resident, Dr Chitrannan Behera is a Assistant Professor and Dr Daya Nand Bhardwaj is a Professor and Head, Department of Forensic Medicine and Toxicology and Dr Mamta Sood is a Associate Professor, Department of Psychiatry, All India Institute of Medical Sciences, New Delhi.

---

**REFERENCES**

3. Accidents and Suicides in India-2010. Published by National Crime Record Bureau, Ministry of Home affairs, Govt of India, Delhi.
Influence of Menopause on the Periodontium

Roby V Emmanuel, Shiba Neelakantan K

INTRODUCTION

Periodontium consists of the supporting structures of the teeth including the cementum, periodontal ligament, alveolar bone and gingiva (gums). Periodontal disease is a multifactorial condition and a major cause of tooth loss worldwide. Periodontitis is defined as an inflammatory disease of the supporting tissues of the teeth caused by specific microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone with pocket formation, recession or both. The initial stage is inflammation of the gingiva (gingivitis). The clinical feature that distinguishes periodontitis from gingivitis is the presence of clinically detectable attachment loss. This is often accompanied by periodontal pocket formation and changes in the density and height of subjacent alveolar bone. If left untreated periodontitis may lead to loss of tooth. Menopause is defined as the permanent cessation of menstruation due to loss of ovarian follicular function, and usually takes place between 45 and 55 years of age.

Effects of Menopause on Periodontium

During menopause, periodontal symptoms can differ for each woman. Menopause hormonal imbalances can even affect other aspects of oral health, such as health condi-
tions in the salivary glands and the jawbone. In a model proposed by Genco and Grossi\(^7\) for oestrogen deficiency as a risk factor for periodontal disease it has been observed that oestrogen deficiency leads to more production of bone-resorbing cytokines produced by immune cells (monocytes and macrophages) and osteoblasts. The host immune system produces more inflammatory cytokines that activate osteoclasts, which reabsorb bone when challenged by products related to periodontal bacterial plaque biofilm by bone-resorbing factors such as lipopolysaccharides, and toxins. For an oestrogen deficient woman to show signs of periodontitis, presence of dental plaque with pathogenic bacteria may be required.\(^4\)

The menopause and the lack of ovarian steroids are known to promote important changes in connective tissue.\(^5\) The mechanisms involved in this influence are not completely understood, but it is thought to be related to the action of oestradiol on the connective tissue.\(^5\) The menopause triggers a wide range of changes in women’s bodies, and the oral cavity is also affected. Although elevated levels of ovarian hormones, as seen in pregnancy and oral contraceptive usage, can lead to an increase of gingival inflammation with an accompanying increase in gingival exudates,\(^7\) conversely, the menopause—the absence of ovarian sex steroids—has been related to a worsening in gingival health, and hormonal replacement therapy seems to ameliorate this trend.\(^8\)

In menopause oestrogen deficiency induces cancellous as well as cortical bone loss. Highly increased bone resorption in cancellous bone leads to general bone loss and destruction of local architecture because of penetrative resorption and microfractures. In cortical bone the first response of oestrogen withdrawal is enhanced endocortical resorption. Later, also intracortical porosity increases. These lead to decreased bone mass, disturbed architecture and reduced bone strength.\(^9\) Postmenopausal women represent a subpopulation with unique factors. Oestrogen deficiency after menopause\(^10,11\) and consequent loss of bone mineral density\(^12,13\) have been shown to be associated with increased rate of tooth loss. These relationships may be explained by increased severity of periodontal disease\(^14,15\) and decreased bone mineral density\(^17,18\) in oestrogen deficiency.

Osteoporosis is caused by an uncoupling of the bone resorption/formation process with an exaggeration of resorption, reduction in bone formation or a combination of both. In most cases, postmenopausal osteoporosis is due to an abnormal increase in resorption or demineralisation and not a decrease in bone formation or remineralisation. Generalised bone loss from systemic osteoporosis may render the jaws susceptible to accelerated alveolar bone resorption. The compromised mass and density of the maxilla or mandible in a patient with systemic osteoporosis also may be associated with an increased rate of bone loss around the teeth or the edentulous ridge. Recent studies support the hypothesis that systemic bone loss may contribute to tooth loss in healthy individuals, and women with low bone mineral density tend to have fewer teeth compared to controls.

Although residual ridge resorption was thought to be a local problem caused or promoted by disuse, inflammation or mechanical factors, there now appears to be some evidence to support the idea that it is also a systemic problem. Several reports show a relationship between residual ridge reduction and osteoporosis. A correlation between mandibular basal bone mineral density and hip bone mineral density has been established. Another study suggests that severe osteoporosis that significantly reduces the bone mineral content of the jaws may be associated with less favourable attachment level in the case of periodontal
disease. Recent studies suggest that postmenopausal osteoporosis is a risk indicator for periodontal disease in postmenopausal white women.19

**Oral Manifestations of Menopause**

A number of physical changes are observed related to menopause including some that occur in the oral cavity. Changes in the oral mucosa occurring in menopausal women may vary from an atrophic to a pale appearance. The gingiva may appear dry and shiny, bleed easily and range from an abnormally pale colour to tissue that is very erythematous. However, some menopausal women with oral discomfort exhibit a clinically normal oral mucosal appearance, suggesting that oral discomfort may be due to other causes. Hormone replacement therapy (HRT) has been of some benefit in reducing oral discomfort in those who have both abnormal and normal mucosal appearance. Other oral symptoms and complaints of the menopausal patient including xerostomia, abnormal taste sensation and burning sensations.

Menopause may be associated with significant adverse changes in the orofacial complex. Women appear to experience an increase in oral symptoms that may result from endocrine disturbances (reduced oestrogen), calcium and vitamin deficiency and various psychological factors during their menopausal years.20,21

They may complain of dry mouth because of decreased salivary secretion, as well as a burning sensation of the mouth and tongue. Taste sensation may change, causing frequent complaints of a metallic taste.22 Also during menopause, women may experience dysesthesia, dental caries, periodontitis and an osteoporotic jawbone unsuitable for conventional dental devices and implants. Some women develop concurrent senile atrophic gingivitis, in which an abnormal paleness of the gingival tissues develops. Other people develop a condition known as menopausal gingivostomatitis, which is characterised by gingivae that are dry and shiny, bleed easily and range in colour from abnormally pale to erythematous.23

**CONCLUSION**

In this context it is important that physicians be aware of the associations between menopause and periodontal problems. A common underlying mechanism may be involved which could lead to loss of bone in the spine and hips which could result in loss of alveolar bone in the jaws, increase the severity of periodontitis and eventually lead to loss of tooth. Patients need proper guidance from the physicians regarding the influence of menopause on the periodontium and reference to a periodontist at the first sign of periodontal disease because both the conditions can be managed better when diagnosed in the early stages.

**About the Authors**

Dr Roby V Emmanuel is a Professor, Department of Periodontology and Oral Implantology, Dr Shiba Neelakantan K is a Senior Lecturer, Department of Oral Medicine and Radiology, People’s College of Dental Sciences and Research Centre, Bhanpur, Bhopal, Madhya Pradesh.
REFERENCES

Introduction
The histopathological diagnosis was angiomyxoma of the vulva. Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumour of unknown aetiology, usually occurring in the pelvi perineal region of females, in the reproductive age group. It is a rare tumour, only about 250 cases have been reported till 2010. AAM is a slow growing neoplasm occurring almost exclusively in women of reproductive age group. The female: male ratio is 6:1. It is called aggressive because of its locally infiltrative behaviour. AAM has high recurrence rate which is attributed to incomplete surgical excision. Hence long-term careful follow up is required for the early detection and treatment of recurrence.

Discussion
The term AAM was coined by Steeper and Rosai in 1983 for a morphologically distinctive, slow growing myxoid neoplasm occurring in the genital, perineal and pelvic regions of adult females. AAM has a wide range of distribution between 16–70 years but peak incidence occurs in the 3rd decade. It occurs predominantly in females, but AAM is also reported in the inguinal region, scrotum and pelvic cavity in males. The female: male ratio of AAM is 6:1. AAM is a slow growing tumour, usually reaches large size of >10 cm by the time of presentation.

It clinically presents as a painless slow growing soft tissue mass in pelviperineal region, often misdiagnosed as Bartholin cyst, periurethral cyst or hernia. AAM is locally invasive, aggressively infiltrates the paravaginal and pararectal soft tissues. Grossly AAM is a soft, non-defined lobulated tumour with myxoid changes.

Microscopically the tumour is composed of spindle or stellate shaped cells with thick walled blood vessels scattered in a myxoid matrix; multinucleated giant cells are rarely seen. Cytological atypia and mitotic figures are rare or absent. The tumour cells express vimentin, desmin and smooth muscle antigen (SMA) and are negative for S-100. The tumour cells express oestrogen and progesterone receptors. Cytogenetic and molecular genetic analysis shows rearrangements in chromosomal region 12q13–15; t (8;12) (p12;15) causing dysregulation of HMGA2 gene resulting in over expression of HMGA2 in AAM. HMGA2 is positive in most aggressive angiomyxomas and is useful in the diagnosis, as most mesenchymal tumours which closely mimic AAM are negative for HMGA2. The conditions mimicking AAM are angiomyofibroblastoma, superficial angiomyxoma, fibroepithelial stromal polyp, cellular angiofibroma, myxoid neurofibroma, myxoid leiomyoma and myxofibrosarcoma.

Wide local excision is the treatment of choice. Except for the positive surgical margins, there are no clinical or histological predictors for tumour recurrence and hence effort should be towards obtaining adequate clearance with tumour free resected margins, which is achieved by wide local excision but this can cause significant morbidity due to its large size and its proximity to genitourinary and anorectal structures. Most often

Case of the Month
Woman Presented with a Soft Globular and Pedunculated Mass in Labia Majora
Sreelatha Sampath Kumar, Ashwini Rani, BR Vani

AGGRESSIVE ANGIOMYXOMA
the tumour is removed incompletely as it has the same consistency as that of normal connective tissue. Hence because of the highly infiltrating borders and incomplete excision, AAM has a high rate of local recurrence of 30%. Metastasis is rarely seen. Preoperative angiographic embolisation, preoperative external beam irradiation and intraoperative electron beam radiotherapy are said to be useful in decreasing the chances of local recurrence to some extent. HMGA2 can be used in evaluating margins of the resected specimens of AAM, in identifying foci of residual or recurrent tumour.

Long-term follow up is mandatory for the early diagnosis and treatment of local recurrence and metastasis. Imaging procedures as CT scan and MRI help in preoperative evaluation and post operative follow up as tumour is non-defined clinically. The presence of oestrogen receptors in tumour and its enlargement in pregnancy suggest the possibility of hormone dependence of AAM. Hence GnRH agonists are suggested for the treatment of recurrent cases and also inoperable primary cases.

Radiotherapy is avoided except in advanced inoperable cases because of the risk of sarcomatous transformation.

**Summary**

AAM is a rare benign neoplasm occurring in females of reproductive age group in the pelvi perineal region, that can be mistaken both clinically and histologically for several conditions. Though rare, because of its locally invasive and high propensity of recurrence; AAM should be included as one of the differential diagnosis for any vaginal mass.

**REFERENCES**


**About the Authors**

Dr Sreelatha Sampath Kumar and Dr BR Vani are Associate Professor, Department Obstetrics and Gynaecology and Dr Ashwini Rani is a Junior Resident, Department Obstetrics Pathology, ESICMC and PGIMSR, Rajajinagar, Bangalore.
Molar Pregnancy with Viable Foetus Progressed to Term – Case Report

Madhushree Vijayakumar, Roopashree

INTRODUCTION

The incidence of mole with coexisting normal foetus is 1 in 100,000 pregnancies. Partial hydatidiform mole differs from complete mole by its focal distribution, its slower transformation, the presence of an embryo/foetus and most often with the triploid karyotype (Figure 1).

Diagnosis could be established by ultrasound which most often reveals greatly enlarged placenta relative to the size of uterine cavity, cystic spaces within the placenta, an amniotic cavity either empty/amorphous foetal echoes, well formed but growth retarded foetus either dead or alive.

We describe a case of molar change in a placenta that was associated with a normal foetus and how the pregnancy progressed.

Case Report

A 25 year old primigravida who conceived spontaneously on folic acid supplementation had uneventful first trimester with no hyperemesis or vaginal bleeding. Viability scan was done at 7–8 weeks gestational age showed a single gesta-
CASE STUDY

Functional sac, CRL 1.1 cms, corresponding to 7.3 weeks good cardiac activity, perigestational sac haemorrhage of size 1.4 cms seen just above the internal os (Figure 2). The routine ANC profile was within normal limits.

At 12+ weeks NT scan was done which showed molar tissue at the right fundal end of uterine cavity of the volume 48 cc, with a healthy live foetus of 12.5 weeks gestational age. NT was 1.4 mm, nasal bone was visible gross morphology of the foetus appeared normal, liquor was adequate (Figure 3).

Mother was doing well. She had no hyperemesis and no bleeding per vaginum. Blood pressure was within normal limits. She had no proteinuria and her blood sugar levels were within normal limits.

She was referred to a Foetal medicine centre for further evaluation. The couple were counseled regarding the ongoing gestation with the molar transformation of a part of the placenta (Figure 4) and was advised a chorionic villus sampling to determine the karyotype of the foetus. Initial FISH report was normal karyotype the follow up culture after 3 weeks also was normal.

She was on regular antenatal visits. Anomaly scan at 21–22 weeks showed no gross anomaly in the foetus the persistence of molar changes of placenta in the fundus. Uterine artery Doppler was normal follow up with growth scans at 28 and 32 weeks showed adequate interval growth and adequate liquor. Pregnancy progressed uneventfully.

Term scan showed a single live 34–35 weeks gestational age grossly normal appearing baby weighing 2400 g, in cephalic presentation, good biophysical profile and a still persisting molar change at the fundus.

At 36 weeks of gestation, her blood pressures were found high with proteinuria 1+. She was started on alpha methyl dopa 250 mg thrice daily, with which her blood pressures remained under control. Her PET profile remained within normal limits. At 39 weeks labour was induced with Dinoprostone gel in view of pre-eclampsia. As labour progressed timely
amniotomy was done and blood stained liquor was drained, suggestive of abruption placenta, examination revealed face presentation.

A decision for emergency LSCS was taken. Live girl baby was extracted with good APGARS, and birth weight of 2.9 kg, placenta and membranes were delivered in toto. A retroplacental clot of about 200 g was seen, hydropic changes in a part of the placenta was also noted (Figure 5). It was sent for histopathological examination

On histopathological examination, grossly placenta measured 15X15X3 cms, weighing 620 g. Insertion of cord was peripheral. Membranes were complete, cord measured 60 cms, cut surface showed 3 vessels and the hydropic part of placenta measured 11X8X1.5 cm (Figure 6). On its surface, it reveals multiple vesicles filled with clear fluid.

On microscopic examination, revealed enlarged villi with hydropic degeneration of the stroma, most villi showed fluid filled cisterns (Figure 7), trophoblastic layer showed focal florid hyperplasia, many villi were necrotic. It was reported as molar transformation (Figure 8).

Post operative period was uneventful, her blood pressures remained normal, did not require any antihypertensives. She was followed up with serial Hcg. 3 Weeks post partum her β hcg was 21.73 m IU/ml, 6 weeks post partum β hcg 8.2 m IU/ml, at 9 weeks postpartum β hcg 2 m IU/ml. Contraceptive options were discussed, she opted barrier method.

DISCUSSION

The formation of moles is complex and it is not easily divisible into so called partial and complete moles. Rather individual genetic study is needed to make an accurate diagnosis because macroscopic or microscopic examination alone fails to assess the complexity of these entities. When a foetus is present in conjunction with partial mole, it generally exhibits the stigmata of triploidy, including growth restriction, multiple congenital malformations. This is compatible with both...
CASE STUDY

foetal and placental development but not long term survival. Cytogenetically partial moles usually have triploid karyotype with the extra haploid set of chromosomes of paternal derivation. Whereas complete moles have a diploid karyotype that is entirely of paternal origin.\(^6\)

Hydatidiform mole with a coexisting foetus can be established by the partial mole syndrome or by a twin pregnancy where the other conceptus has degenerated into a mole.\(^7\) The theoretical explanation that it resulted from a twin dizygotic pregnancy in which one twin had developed normally and the other had degenerated into a complete mole. The difference between a partial and a complete mole cannot be firmly established by ultrasound because they both present with the same vesicular pattern.\(^8\) In our case ultrasound revealed normal appearing foetus, but also a normal placenta connecting with sharply defined molar tissues. Since the normal placenta which was separate from molar tissues can be well defined, a complete mole pregnancy with a concurrent foetus can be diagnosed.

Risk of developing persistent gestational trophoblastic tumour should be kept in mind. The determining factor seems to be whether the molar component is partial or complete. Partial moles have a relatively low incidence of 4 percent of producing pGTT when compared to 20 percent risk in complete moles.\(^4\) Careful surveillance for the pGTT is warranted.

Literature review have reported that pregnancies which continue beyond the 28\(^{th}\) week, a surviving child may be expected in ~70% of pregnancies, the risk for intrauterine or neonatal death being ~30%. Persistent trophoblastic disease was reported in 9.1% of those who had continued.\(^9\)

CONCLUSION

Molar pregnancy with a coexisting foetus progressing to term with good outcome is an extremely rare entity. They present...
with varied complications. In few cases pregnancies may have to be terminated. Optimum management of these cases poses significant clinical dilemma to both patients and clinicians.

About the Authors
Dr Madhushree Vijayakumar is a Consultant and Dr Roopashree is a Resident, Department of Obstetrics and Gynaecology, St. Philomena’s Hospital, Bangalore.
INTRODUCTION

Gestational diabetes mellitus (GDM) is a controversial subject in obstetrics. It is defined by the National Diabetes Data Group in 1985 as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy. The first case report of GDM appeared in 1824, which described a mother with thirst, polyuria and glycosuria and the death of a macrosomic infant from shoulder impaction. Historically, there has been a lot of controversy over most aspects of GDM, including screening, diagnosis, risks, treatment, and the relationship between GDM and type II diabetes mellitus. Recently, several major studies have substantially resolved these areas of controversy, eg, the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study, the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), and the Maternal-Fetal Medicine Units Network treatment of mild gestational diabetes (MFMUN-GDM) clinical trials, which will be discussed further in this article.

INCIDENCE

The reported incidence of GDM varies with diagnostic criteria and characteristics of the population being studied (eg, age, body build, ethnic origins). The United States reported an incidence of 3–8%, with a rising trend in more recent publications. The United Kingdom reported an incidence of 2% and Canada described 3.8%. In Hong Kong, a study performed in a university teaching hospital, Queen Mary Hospital, showed that of the 16,383 women managed in the period 1998–2001, the prevalence of GDM increased from 1.3% (≤ 20 years), 2.5% (20–24 years), 6.2% (25–29 years), 10.3% (30–34 years), 21.7% (35–39 years), and 31.9% (≥ 40 years), respectively, from the youngest to the oldest cohort (P < 0.001). Another study performed in a different university teaching hospital in Hong Kong, Prince of Wales Hospital, found that the prevalence of GDM was 14.2%. In our hospital, a regional hospital with around 6,000 deliveries per year, the incidences of GDM in 2008 and 2009 were 13.2% and 14.2%, respectively.
SCREENING AND DIAGNOSIS

The diagnostic criteria of GDM were initially established more than 40 years ago, and these criteria were not designed to identify pregnant women at increased risk for adverse perinatal outcomes but rather women at higher risk for the development of diabetes after pregnancy. Following the publication of the HAPO study, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) established a new set of diagnostic guidelines (Figure 1). As more and more women suffer from diabetes before pregnancy, the IADPSG recommends screening women with risk factors at the booking visit by using random plasma glucose, fasting plasma glucose, or glycated haemoglobin A1c paired with diagnostic thresholds, according to the current guidelines for the diagnosis of pre-existing diabetes. Moreover, GDM can be diagnosed at the booking visit with a fasting plasma glucose between 5.1 mmol/L and 7.0 mmol/L, hence lowering the thresholds of GDM in most guidelines. They also recommend that all women who do not have diabetes should be screened at 24–28 weeks’ gestation with the 75-g oral glucose tolerance test. In contrast to the World Health Organization criteria which use an abnormal fasting or 2-hour plasma glucose for the diagnosis of diabetes, the IADPSG suggests that an abnormal 1-hour plasma glucose is adequate for the diagnosis. They also take into account the continuous association between maternal blood glucose concentrations and adverse perinatal outcomes as seen in HAPO. The agreed thresholds represent an odds ratio of 1.75 for birth weight, cord C-peptide, and fetal body weight being greater than the 90th percentile, relative to the odds of those outcomes at mean glucose values. Applying this system of testing and di-

---

**Figure 1. Flow chart showing guidelines as suggested by IADPSG**

At booking visit, all or high-risk women should have FG, HbA1c, RG tested

- DM if FG ≥ 7.0 mmol/L, or HbA1c ≥ 6.5%, or RG ≥ 11.1 mmol/L
- Normal
- GDM if FG ≥ 5.1 mmol/L, but < 7.0 mmol/L

75-g OGTT at 24–28 weeks

- DM if FG ≥ 7.0 mmol/L
- GDM if FG ≥ 5.1 mmol/L, or 1hG ≥ 10.0 mmol/L, or 2hG ≥ 8.5 mmol/L

---

1hG = 1-hour plasma glucose in 75-g oral glucose tolerance test; 2hG = 2-hour plasma glucose in 75-g oral glucose tolerance test; DM = diabetes mellitus; FG = fasting glucose; GDM = gestational diabetes mellitus; HbA1c = glycated haemoglobin A1c; IADPSG = The International Association of Diabetes and Pregnancy Study Groups; OGTT = oral glucose tolerance test; RG = random glucose.
agnostic criteria will probably double the incidence of GDM. 11

RISKS

The HAPO study2 was a 10-year, prospective, blinded, multicentre study, which enrolled 25,505 pregnant women. It aimed at studying the associations between the risks of adverse pregnancy outcomes and the degrees of maternal glucose intolerance less severe than overt diabetes. Exclusion criteria include fasting plasma glucose > 5.8 mmol/L, or the 2-hour plasma glucose * 11.2 mmol/L, or a random plasma glucose * 8.9 mmol/L. It showed an unambiguous, linear, positive association between maternal glycaemia and adverse pregnancy outcomes (eg, birth weight > 90th percentile, caesarean section, cord plasma C-peptide level reflective of fetal hyperinsulinemia, neonatal hypoglycaemia, excess neonatal adiposity, shoulder dystocia or birth injury, neonatal hyperbilirubinaemia, pre-eclampsia).12,13

Table 1. Risks factors of gestational diabetes*  

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Odds ratio</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overweight</td>
<td>2</td>
<td>Torloni et al, Chu et al</td>
</tr>
<tr>
<td>Obesity</td>
<td>3.7</td>
<td>Torloni et al, Chu et al</td>
</tr>
<tr>
<td>Severe obesity</td>
<td>7</td>
<td>Torloni et al, Chu et al</td>
</tr>
<tr>
<td>Prior gestational diabetes</td>
<td>23</td>
<td>McGuire et al</td>
</tr>
<tr>
<td>Prior macrosomic infant</td>
<td>3.3</td>
<td>McGuire et al</td>
</tr>
<tr>
<td>Maternal age greater than 25 y</td>
<td>1.4</td>
<td>Cypryk et al</td>
</tr>
<tr>
<td>Maternal age greater than 35 y</td>
<td>2.3</td>
<td>Xiong et al</td>
</tr>
<tr>
<td>Multiple gestation</td>
<td>2.2b</td>
<td>Rauh-Hain et al</td>
</tr>
<tr>
<td>South East Asian</td>
<td>7.6b</td>
<td>Dornhorst et al</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.4b</td>
<td>Dooley et al</td>
</tr>
<tr>
<td>African American</td>
<td>1.8b</td>
<td>Dooley et al</td>
</tr>
<tr>
<td>Polycystic ovarian syndrome</td>
<td>2.9</td>
<td>Toulis et al</td>
</tr>
<tr>
<td>Parent with diabetes</td>
<td>3.2</td>
<td>Kim et al</td>
</tr>
<tr>
<td>Sibling with diabetes</td>
<td>7.1</td>
<td>Kim et al</td>
</tr>
<tr>
<td>Periodontal disease</td>
<td>2.6</td>
<td>Xiong et al</td>
</tr>
<tr>
<td>Low maternal birth weight</td>
<td>1.9</td>
<td>Seghieri et al</td>
</tr>
</tbody>
</table>

The risk factors and health risks of GDM are summarized in Tables 1 and 2.

TREATMENT

The ACHOS3 and the MFMUN-GDM4 clinical trials demonstrated that diagnosis and treatment of GDM were worthwhile because these reduced the risk of many adverse pregnancy outcomes of GDM. In both studies which were double blind, women diagnosed with GDM in the late second and early third trimesters were randomized to two groups, ie, routine care or intervention. Intervention in both trials included

Table 2. Health risks of gestational diabetes*  

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Odds ratio</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth trauma</td>
<td>Hyperinsulinaemia</td>
<td>Respiratory distress syndrome</td>
</tr>
<tr>
<td>Increased caesarean delivery</td>
<td>Cardiomyopathy</td>
<td>Hypoglycaemia</td>
</tr>
<tr>
<td>Pre-eclampsia/Gestational hypertension</td>
<td>Stillbirth</td>
<td>Hypocalcaemia</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>Large for gestational age/macrosomia</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>Birth trauma</td>
<td>Hyperviscosity, Polycythemia, Hyperbilirubinaemia, Cardiomyopathy</td>
</tr>
</tbody>
</table>

dietary modification, blood glucose monitoring, and, if needed, insulin treatment. In the ACHOIS trial, a composite measure of serious perinatal complications (defined as one or more of death, shoulder dystocia, bone fracture, and nerve palsy) was reduced by diagnosis and intervention (adjusted odds ratio, 0.33; 95% confidence interval, CI, 0.14–0.75; \( P = 0.01 \)). A similar composite measure in the MFMUN-GDM trial was also decreased but was not statistically significant (relative risk, 0.87; 97% CI, 0.72–1.07; \( P = 0.14 \)). In both studies, rates of large-for-gestation-al-age (LGA)/macrosomia, pre-eclampsia and maternal pregnancy weight gain were reduced by intervention. Rates of shoulder dystocia and caesarean section were significantly decreased by treatment in the MFMUN-GDM trial only. Rates of induction of labour and of admission to the neonatal unit were increased by treatment in the ACHOIS trial only. Generally, these two trials showed that identification and treatment of GDM with a standard approach improved pregnancy outcomes.

**DIETARY MODIFICATION**

The scientific evidence for making nutritional recommendations for women with GDM is limited. Referral to nutritional counselling should ideally occur within 48 hours of the diagnosis of GDM. The first meeting with a professional dietitian should be arranged within 1 week of the referral, and a total of three visits are suggested. Throughout the pregnancy, the diet should be adjusted and individualized to meet the patient’s food choice, financial needs, culture, habits, weight gain, physical activity, and blood glucose goals.

The Dietary Reference Intakes recommends no increase in calories for the first trimester but an additional 340 kcal/day during the second trimester and 452 kcal/day during the third trimester. In obese women with GDM, a 30% caloric restriction help to avoid ketonuria or an increase in free fatty acids, while improving glycaemic control. A more severe caloric restriction is not recommended. The National Institute for Clinical Excellence (NICE) guidelines in the UK recommend that women with GDM whose pre-pregnancy body mass index is above 27 kg/m² should restrict caloric intake (to 25 kcal/kg/day or less) and engage in moderate exercise (of at least 30 minutes daily).

The goal of fractionating food intake into three meals and two to three snacks in between meals is to distribute the glucose intake throughout the day in order to control the postprandial glucose, while at the same time maintaining a satisfactory nutritional intake. The evening snack decreases the night-time ketogenesis related to fasting. Generally, 40–45% of the calories in the daily diet come from carbohydrates, but this must be individualized. One study showed that in women with GDM, carbohydrate restriction to < 42% led to fewer LGA infants, reduced rates of caesarean sections for macrosomia and cephalopelvic disproportion, and reduced need for insulin treatment, compared with a higher carbohydrate content (45–50%).
Few studies have focused on the benefit of carbohydrates with a low glycaemic index (GI), which is a measure of how much each gram of available carbohydrate in the food increasing a person’s blood glucose level following consumption of the food, relative to consumption of glucose. Food with carbohydrates that break down quickly during digestion and release glucose rapidly into the bloodstream tend to have a high GI, while food with carbohydrates that break down more slowly, releasing glucose more gradually into the bloodstream, tend to have a low GI. There have been no randomized studies with sufficient sample size to draw a conclusion on the benefits of carbohydrates with a low GI. Increased dietary fibre intake is traditionally recommended for women with GDM, as it may reduce the postprandial blood glucose. But no proof exists that extra dietary fibre intake is beneficial in these women.

**PHARMACOTHERAPY**

Drug treatment is necessary in 7–20% of women with GDM when, despite dietary modification, there is insufficient glucose control, high levels of fasting glucose, suboptimal weight gain (due to caloric restriction), or persistent hunger sensation. The Fifth International Workshop-Conference on Gestational Diabetes recommends the following blood glucose concentrations: fasting plasma glucose, 5.0–5.5 mmol/L; 1-hour postprandial plasma glucose, < 7.8 mmol/L; and 2-hour postprandial plasma glucose, < 6.7–7.1 mmol/L. The NICE guidelines recommend drug treatment if diet and exercise cannot control the blood glucose for 1–2 weeks, or if ultrasound shows possible fetal macrosomia (abdominal circumference above the 70th percentile) at diagnosis.

**Oral Hypoglycaemic Agents**

Glyburide (or glibenclamide) is a second-generation sulfonylurea. It binds to receptors that are associated with the adenosine triphosphate-dependent potassium channels of pancreatic β cells to increase insulin secretion and insulin sensitivity of peripheral tissues. The onset of action takes approximately 1 hour with the peak level at 4 hours after intake. Studies on the placental transfer of glyburide are contradictory. In vitro studies showed minimal placental transfer, but the fetal response to various dosages of glyburide is not completely known. A meta-analysis by Moretti et al reported no differences between the insulin and glyburide groups with regard to birthweight, LGA/ macrosomia, gestation at delivery, admissions to neonatal units, or neonatal hypoglycaemia.

Metformin belongs to the biguanide group. It inhibits hepatic gluconeogenesis and glucose absorption, and stimulates glucose uptake in peripheral tissues. The onset of action takes approximately 1 hour with the peak level at 2–4 hours after intake. Metformin does cross the placenta. Because it acts as an insulin sensitizer in peripheral tissues rather than as an insulin analogue, it is believed that fetal metabolism is less likely to be affected. The Metformin in Gestational Diabetes (MiG) trial of 751 women showed similar perinatal complications in both the metformin and insulin groups, with better acceptability in the metformin group; but subsequent insulin was indicated in 46.3% of women taking metformin.

Long-term safety data on infants whose mothers were treated with glyburide or metformin are lacking. Early neonatal complications, such as hypoglycaemia, are not common and do not differ very much from those resulting from insulin therapy. When counselling patients, health carers can reassure them that the rates of congenital malformations with the use of oral hypoglycaemic agents and insulin do not differ. The maternal glucose control (fasting blood glucose and 2-hour postprandial) by oral hypoglycaemic agents and insulin is also comparable.

Acarbose, an alpha glucosidase inhibitor, has been used less often. Preliminary studies showed that it was effective in decreasing postprandial hyperglycaemia in GDM, but its use has been limited by its side effects, like abdominal cramp-
Further studies are needed to better evaluate the potential placental transfer of this drug, as small amounts of acarbose can be absorbed into the bloodstream.

**Insulin**

Traditionally, insulin has been regarded as the standard treatment for diabetes, especially when diet and exercise fail to control the maternal blood glucose and there is no risk of placental transfer of insulin to the fetus.

Insulin requirements are not constant throughout the day: it is low at night with a sharp rise at dawn, followed by a gradual decrease during the rest of the day. Women in the first trimester are at risk of hypoglycaemic events because of emesis, and blood glucose levels should be closely monitored with appropriate adjustment of insulin. After the second trimester, insulin requirements rise. During labour, short-acting insulin should be used to achieve optimal glucose levels of between 4 and 8 mmol/L and to prevent neonatal hypoglycaemia. After delivery, glycaemic control must be relaxed to prevent maternal hypoglycaemia, especially in breastfeeding women. Insulin therapy should be stopped in women who have not taken insulin before pregnancy, while those women who are taking insulin for pre-existing diabetes should resume their pre-pregnant insulin dosages.

There are two types of insulin: human insulin and insulin analogue. The short-acting insulin analogue lispro has also been shown to be safe in observational studies. However, there is no safety data available on the long-acting insulin analogues detemir and glargine; both are prescribed off-label. Therefore, long-acting human insulin should be used instead.

**ANTENATAL MANAGEMENT**

Once GDM is diagnosed, visits to health carers or dietitians by the pregnant women should be made at least every 1–2 weeks and more frequently if complications occur. There is no consensus on the frequency and timing of antenatal surveillance tests in women with GDM. It is crucial to manage women, who do not comply with advice, require drugs, have macrosomic or growth-restricted fetuses, or have other obstetric complications, as though they had pre-existing diabetes and to begin close antenatal monitoring (eg, the NICE guidelines suggest anomaly scan, echocardiography, growth scan at 28, 32 and 36 weeks’ gestation, tests of fetal wellbeing after 38 weeks’ gestation). History review, blood pressure measurement, and urine albumin testing to diagnose pre-eclampsia are also essential at every visit. In an attempt to prevent macrosomia and to guide the treatment, a randomized trial compared ultrasound performed at 32 weeks’ gestation with ultrasound at both 28 and 32 weeks’ gestation. The rate of macrosomia was significantly higher in the group assessed only at 32 weeks (71.1% vs 33.3%; \( P < 0.005 \)).

The mode and timing of delivery of women with GDM is controversial because sufficient data are lacking to make a recommendation.

Induction of labour in women with insulin-treated diabetes at 38 weeks’ gestation is intended to reduce the risk of stillbirth. One study failed to detect a benefit to expectant management beyond 38 weeks’ gestation, as the rate of caesarean delivery was not reduced but rather the rates of LGA infants and shoulder dystocia were increased. For uncomplicated GDM, no strong evidence exists to support earlier induction of labour, which was also confirmed by a Cochrane review of randomized trials on elective delivery in women with diabetes.

Prophylactic pre-labour caesarean section using estimated fetal weight by ultrasound has been proposed but is controversial. Recommendations concerning the lower estimated fetal weight thresholds for prophylactic caesarean section vary from 4,000 to 4,500 g. Both the American College of Obstetricians and Gynecologists and the Royal College of Obstetricians and Gynaecologists recommend prophylactic caesarean section if the estimated fetal weight is > 4,500 g. Another issue is the inaccuracy of ultrasound in estimating fetal weight, which leads to an increase in unnecessary caesarean deliveries and, therefore, caesarean-associated maternal and fetal morbidities, and additional health-care costs.

**POSTPARTUM MANAGEMENT**

Approximately 50% of women with GDM will develop type 2 diabetes within 5 to
Diagnostic testing for diabetes is appropriate 6 weeks after delivery. It is unclear whether a traditional 2-hour 75-g oral glucose tolerance test or fasting plasma glucose test may be more useful at this time. The frequency of follow-up blood glucose tests for early detection of impaired glucose tolerance or diabetes varies from annual to triennial. Advice on postpartum weight loss, which may help reduce the occurrence of type 2 diabetes mellitus, includes breastfeeding, dietary modification, and exercising for at least 150 minutes every week.  

CONCLUSION

Without further cost analyses and confirmation of results from randomized intervention trials, the IADPSG guidelines are unlikely to be widely adopted worldwide. Without a uniform diagnosis, research on risks and management is difficult. Women with GDM should be treated with dietary modification, appropriate exercise, and drugs, if necessary. Oral hypoglycaemic agents (eg, glyburide, metformin) are as useful as but not better than insulin alone in terms of early pregnancy outcomes. 

About the Authors

Dr Chan is a resident trainee, and Dr Lau and Dr Leung are consultants, practicing in the Department of Obstetrics and Gynaecology, Kwong Wah Hospital, Kowloon, Hong Kong SAR.

REFERENCES


